21.54USDMkt Cap: 755.92M USDP/E: —Last update: 2026-05-21
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients wit…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap755.92M USD
Enterprise Value514.07M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.24M USD
Revenue/Share—
Last Price21.54 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.81
PEG—
EV/EBITDA-6.66
EV/Revenue—
P/S—
P/B3.10
EPS (TTM)-2.43
EPS (Forward)-3.17
52W Range
20.6095% of range21.58
52W High21.58 USD
52W Low20.60 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.84%
ROA-34.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.77M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield-5.28%
Net Debt-241.85M USD
Net Debt/EBITDA3.13
Balance Sheet
Debt/Equity0.16
Current Ratio20.52
Quick Ratio20.11
Book Value/Sh6.943 USD
Cash/Share7.516 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)35.34 USD
Target Range24.00 USD – 50.00 USD
# Analysts10
Ownership
Shares Out.35.09M
Float23.95M
Insiders4.55%
Institutions76.86%
Short Interest
Short Ratio4.6d
Short % Float5.42%
Short % Out.4.53%
Shares Short1.59M
Short (prev mo.)2.05M
Technical
SMA 5023.38 (-7.9%)
SMA 20014.73 (+46.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)225.63K
Avg Vol (10d)356.61K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—